about
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsThrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation.Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapyRisk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosisNew treatments for myelodysplastic syndromesInhibitors of DNA methylation in the treatment of hematological malignancies and MDS.Similarities and differences between therapy-related and elderly acute myeloid leukemia.Incidence of acute myeloid leukemia after breast cancer.Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia.Outcome of therapy-related myeloid neoplasms treated with azacitidineTreatment of acute leukaemias with monoclonal antibodies: current status and future prospects.Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemiaCD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.Why methylation is not a marker predictive of response to hypomethylating agents.PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.Iron in Hodgkin's lymphoma.Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.Clonal evolution in therapy-related neoplasms.Treatment of Low-Blast Count AML using Hypomethylating Agents.PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma.Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma.Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias.Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia.Fanconi anemia gene variants in therapy-related myeloid neoplasms.Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes.Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome.
P50
Q28073464-7003E3F6-142E-413C-9C63-AA98985FC2BEQ33346218-FFD3CB43-6801-41AF-AD11-5095310D12DDQ33779309-2513788D-CC74-4257-AB26-0F2D0089609BQ33827846-87E40DB3-2F62-4B24-B957-642D72EEB263Q33877952-606902B6-E08D-4F0A-AC53-32A55BBED605Q34198047-A40A8F91-5A90-4581-9E4B-E323BA6F2127Q34549290-7E208585-70E0-4285-92E8-700CE0096216Q35571293-3F4AFC48-AAA4-4741-BC95-B234B8538111Q35640731-9F5A6866-AC1F-42EB-937B-4C67CF84512FQ35640784-FC97B7EC-66BB-48B5-B513-36A89E304907Q35745087-3A082564-8830-4D90-9AD1-51DAA6D24108Q36165737-2E5FC90C-3BA1-46F3-BA1E-E86F4A0150CBQ36418067-08F8D8DE-3F48-442E-8E2E-525CB0E6B5D9Q36612343-2278D4DF-894D-43C2-B446-111B89653954Q36706850-95B057F6-057E-43CF-BBFD-5442B375B139Q37627821-EA186396-7B39-4D89-A39A-B8A76F68ED0EQ37676259-79FABBD3-0AC0-4A0A-A805-B7EDE21F587FQ37686992-715DE33F-2794-4787-B261-73399773B4E3Q38123547-837B94A4-6848-45AA-A176-195DF1460D70Q38442976-8E3348B9-88CD-4624-BAC5-80F1DCA84D45Q38583509-C11F1CA9-3184-4EBD-BDA8-C82EC2386A05Q38828309-0CA8A86F-8F4E-4C88-B2F5-3223492EFD6AQ38832241-008D92E9-A5D5-4031-B132-BC8D34874D7BQ38860919-053EA701-BDCF-48E0-9716-F7C22914E369Q39026726-CDE00769-4A0A-4D68-9CEF-E6FF712CA74EQ39429687-C4FB6C08-D0CC-4473-BBE0-8E0C3EEA273BQ39805430-EA2BF404-F92D-44B4-B07E-60E29F1725E5Q40163155-8942F235-2A86-41C5-9F9B-5F2B0CDF665AQ40788034-3CB6047C-671E-4D03-BF29-035F3626023BQ40793299-98AB1AB8-139A-4F66-BEB1-5815230FCBFCQ40896172-EC872112-7821-4D77-B06A-5F7A7CC4B781Q40956947-D823539B-97C6-4A9A-A116-6DF944B2ABEFQ41237697-80831A04-31F4-4670-B2AF-F92B7712C61EQ41476969-A2F7AF43-5A63-45F5-B56D-47EED226E568Q42165131-BF90C1D6-2AAA-4311-AB5B-18F4943FC36AQ42421841-D0EEE907-FCF8-418F-947B-0AF424BD74F7Q42640570-AA3FB2A7-4E7A-443C-AB80-9FE461891C97Q42645802-0FE6AF0B-839C-4644-BC69-4536B042FDECQ43135315-55DE4536-0396-49F3-8FBC-42B4E73843E0Q43142221-2AD5A625-E3B5-424D-A37A-4EEE2B5A55CD
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Maria T Voso
@ast
Maria T Voso
@en
Maria T Voso
@es
Maria T Voso
@nl
type
label
Maria T Voso
@ast
Maria T Voso
@en
Maria T Voso
@es
Maria T Voso
@nl
prefLabel
Maria T Voso
@ast
Maria T Voso
@en
Maria T Voso
@es
Maria T Voso
@nl
P106
P1153
7003858678
P21
P214
22151836544820402647
P31
P496
0000-0002-6164-4761
P735
P7859
viaf-22151836544820402647